Gene Therapy Casgevy denied as experimental or investigational by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for gene therapy casgevy are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Casgevy as Experimental — and Why That Label Is Outdated

UnitedHealthcare's "experimental or investigational" denial category is one of the most commonly contested in gene therapy. These denials typically occur when UHC's coverage policy has not yet been updated to reflect FDA approval, when the plan's benefit language excludes newly approved therapies pending an internal evidence review, or when the claim was miscoded in a way that triggered an investigational-drug workflow. Casgevy has received FDA approval; calling it experimental in the post-approval context is factually incorrect and legally contestable.

## Why This Denial Is Appealable

FDA-approved therapies used on-label are not experimental by the standard legal and clinical definition. ACA §2719 and ERISA §503 give you the right to an independent external review, where a clinical IRO — not UHC — decides whether the therapy meets the evidence standard. IROs reviewing gene therapy denials evaluate the totality of the published evidence and the FDA's own determination; plans rarely prevail at external review when their sole basis is "experimental" for an FDA-approved on-label use.

## Federal Appeal Framework

• Internal appeal: File immediately, attaching FDA approval documentation and the prescribing label. Timeline runs from the denial notice — typically 180 days to file.
• External review: Request IRO review if internal appeal is denied. The approximately four-month external-review window begins from the final internal denial. This is often where experimental denials are reversed.
• State protections: Many states have enacted laws prohibiting experimental-therapy denials for treatments that have received FDA approval. Check whether your state's insurance commissioner has relevant guidance.
• Expedited review: Available if delay poses serious health risk.

## Documentation to Gather

1. FDA approval documentation: The publicly available FDA-approved prescribing label and any available FDA approval letter from Drugs@FDA. 2. On-label use confirmation: A letter from your hematologist confirming the prescribed use is within the FDA-approved indication. 3. Professional society guidelines: Reference (without quoting specific numbers) the applicable ASH or relevant hematology society guidelines supporting Casgevy's use for your condition. 4. Published clinical evidence summary: Your hematologist or a medical writer can prepare a brief narrative citing the published literature supporting the therapy — without inventing trial statistics. 5. UHC policy text: Obtain UHC's experimental/investigational coverage policy and identify exactly what evidence standard it applies, so you can respond to each criterion.

## Criteria-Mapping Strategy

UHC's experimental-therapy policy typically requires that a treatment meet a defined evidence threshold (such as general acceptance in the medical community, or citation in peer-reviewed literature). Document, for each criterion: (a) FDA approval satisfies the regulatory-acceptance standard; (b) professional society endorsement satisfies the guideline-acceptance standard; and (c) published peer-reviewed evidence satisfies the literature standard. Map each criterion to a document and attach them as labeled exhibits.